Goldman Sachs
BIIB icon

Goldman Sachs’s Biogen BIIB Stock Holding History

Goldman Sachs’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$193M Sell
1,051,094
-48,272
-4% -$8.89M 0.02% 691
2025
Q4 		$193M Buy
1,099,366
+35,780
+3% +$5.85M 0.02% 653
2025
Q3 		$149M Buy
1,063,586
+392,734
+59% +$53.1M 0.02% 732
2025
Q2 		$84.3M Buy
670,852
+66,155
+11% +$8.24M 0.01% 997
2025
Q1 		$82.7M Sell
604,697
-165,623
-22% -$23.7M 0.01% 880
2024
Q4 		$118M Sell
770,320
-218,721
-22% -$36.9M 0.02% 724
2024
Q3 		$192M Sell
989,041
-431,819
-30% -$90.3M 0.03% 533
2024
Q2 		$329M Buy
1,420,860
+426,495
+43% +$92.7M 0.06% 346
2024
Q1 		$214M Sell
994,365
-101,458
-9% -$23.8M 0.04% 467
2023
Q4 		$284M Buy
1,095,823
+304,978
+39% +$74.9M 0.05% 374
2023
Q3 		$203M Sell
790,845
-34,820
-4% -$9.31M 0.04% 431
2023
Q2 		$235M Buy
825,665
+164,216
+25% +$48.9M 0.05% 360
2023
Q1 		$184M Sell
661,449
-317,433
-32% -$87.8M 0.04% 453
2022
Q4 		$271M Sell
978,882
-418,762
-30% -$118M 0.07% 319
2022
Q3 		$373M Sell
1,397,644
-246,405
-15% -$52.3M 0.09% 193
2022
Q2 		$335M Buy
1,644,049
+333,945
+25% +$68.3M 0.08% 211
2022
Q1 		$276M Buy
1,310,104
+360,864
+38% +$78.5M 0.06% 327
2021
Q4 		$228M Buy
949,240
+149,312
+19% +$38.4M 0.05% 411
2021
Q3 		$226M Sell
799,928
-41,150
-5% -$13.5M 0.05% 378
2021
Q2 		$291M Buy
841,078
+3,518
+0.4% +$1.07M 0.07% 286
2021
Q1 		$234M Buy
837,560
+289,432
+53% +$78.1M 0.06% 321
2020
Q4 		$134M Sell
548,128
-338,247
-38% -$87.3M 0.03% 473
2020
Q3 		$251M Sell
886,375
-451,256
-34% -$126M 0.07% 258
2020
Q2 		$358M Buy
1,337,631
+61,867
+5% +$18.6M 0.11% 173
2020
Q1 		$404M Sell
1,275,764
-495,863
-28% -$150M 0.14% 135
2019
Q4 		$526M Sell
1,771,627
-19,182
-1% -$5.32M 0.13% 141
2019
Q3 		$417M Buy
1,790,809
+606
+0% +$141K 0.12% 160
2019
Q2 		$419M Buy
1,790,203
+124,721
+7% +$28.8M 0.12% 160
2019
Q1 		$394M Sell
1,665,482
-135,739
-8% -$42.7M 0.12% 152
2018
Q4 		$542M Sell
1,801,221
-462,032
-20% -$147M 0.17% 92
2018
Q3 		$800M Sell
2,263,253
-10,049
-0.4% -$3.46M 0.21% 79
2018
Q2 		$660M Sell
2,273,302
-175,551
-7% -$49.4M 0.18% 90
2018
Q1 		$671M Buy
2,448,853
+153,551
+7% +$47.7M 0.17% 99
2017
Q4 		$731M Buy
2,295,302
+178,534
+8% +$57.3M 0.17% 97
2017
Q3 		$663M Buy
2,116,768
+383,275
+22% +$113M 0.16% 95
2017
Q2 		$470M Sell
1,733,493
-5,349
-0.3% -$1.41M 0.12% 145
2017
Q1 		$475M Buy
1,738,842
+440,777
+34% +$125M 0.13% 131
2016
Q4 		$368M Buy
1,298,065
+140,732
+12% +$41.7M 0.1% 174
2016
Q3 		$362M Buy
1,157,333
+25,338
+2% +$7.5M 0.11% 166
2016
Q2 		$274M Sell
1,131,995
-306,114
-21% -$80.7M 0.09% 221
2016
Q1 		$374M Sell
1,438,109
-102,964
-7% -$27.2M 0.12% 141
2015
Q4 		$472M Sell
1,541,073
-157,376
-9% -$45.2M 0.15% 125
2015
Q3 		$496M Buy
1,698,449
+264,751
+18% +$87.4M 0.17% 102
2015
Q2 		$579M Buy
1,433,698
+169,213
+13% +$67.9M 0.18% 92
2015
Q1 		$534M Sell
1,264,485
-538,044
-30% -$212M 0.17% 103
2014
Q4 		$612M Buy
1,802,529
+609,082
+51% +$197M 0.19% 82
2014
Q3 		$395M Sell
1,193,447
-205,027
-15% -$67.6M 0.13% 139
2014
Q2 		$441M Buy
1,398,474
+161,425
+13% +$48.6M 0.14% 133
2014
Q1 		$378M Buy
1,237,049
+89,023
+8% +$28.3M 0.12% 153
2013
Q4 		$321M Buy
1,148,026
+262,589
+30% +$67.9M 0.11% 195
2013
Q3 		$213M Sell
885,437
-158,607
-15% -$35.5M 0.08% 271
2013
Q2 		$225M Buy
+1,044,044
New +$223M 0.09% 231

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs's BIIB Position: Q1 2026 in Review

Goldman Sachs reduced its Biogen (BIIB) stake by 4.4% in Q1 2026, selling an estimated $8.89M and leaving 1,051,094 shares worth $193M. The position accounts for 0.02% of the portfolio, ranked #691.

Goldman Sachs first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $800M in Q3 2018. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Goldman Sachs held 1,051,094 shares of Biogen worth $193M as of Q1 2026.
  • Goldman Sachs sold 48,272 Biogen shares in Q1 2026, an estimated $8.89M.
  • Biogen made up 0.02% of Goldman Sachs's portfolio in Q1 2026, its #691 holding.
  • Goldman Sachs first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Biogen position peaked at $800M in Q3 2018.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.